IHImran Hossain

Imran Hossain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Imran Hossain has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Vascular Endothelial Growth Factor A +936 C/T Polymorphism With Non‐Alcoholic Fatty Liver Disease in a Bangladeshi Population: A Case‐Control Study

    by Rakibul Hasan Shanto, Imran Hossain, Ahmad Niaz Rahman, Fazle Rabbi, Anik Dhar, Sheikh Faisal Asadullah Mahdi, Tarhima Jahan Jerin, Md. Samsul Arafin, Mamun Al Mahtab, Sheikh Zahir Raihan

    Background and Aims: Non‐Alcoholic Fatty Liver Disease (NAFLD) ranges from hepatic steatosis to advanced cirrhosis. Polymorphisms in the vascular endothelial growth factor A (VEGFA) gene can change its expression, potentially altering angiogenesis and advancing disease stage. This study aimed to evaluate the association between the VEGFA +936 C/T polymorphism and susceptibility to NAFLD in a Bangladeshi population. Methods: A case‐control study was conducted including 100 NAFLD patients and 100 controls. NAFLD was diagnosed by ultrasonography. Genotyping was performed using allele‐specific polymerase chain reaction followed by gel electrophoresis. Biochemical parameters were measured using standard enzymatic methods following the manufacturer's instructions. Results: The frequency of the T allele was significantly higher in NAFLD patients compared to controls (22.5% vs. 12%). The control genotype distribution was consistent with Hardy‐Weinberg equilibrium ( χ 2  = 0.2812, p  = 0.60). The Cochran–Armitage trend test indicated an association between increasing T‐allele dosage and NAFLD ( Z = 2.68, p  = 0.007). In logistic regression, the T‐allele was associated with NAFLD in the crude additive model (OR = 2.05, 95% CI: 1.20–3.51, p  = 0.009) and after adjustment for age, sex, BMI, and fasting blood glucose (OR = 2.14, 95% CI: 1.13–4.08, p  = 0.02). Under the dominant model, the association remained significant in both crude (OR = 2.27, 95% CI: 1.22–4.22, p  = 0.01) and adjusted analyses (OR = 2.51, 95% CI: 1.18–5.33, p  = 0.02). NAFLD patients showed significantly higher blood pressure, fasting blood glucose, HbA1c, total cholesterol, ALT, and AST, with lower HDL, while body mass index didn't differ significantly between groups. Conclusion: This study demonstrated a significant association between the VEGFA +936 C/T polymorphism and susceptibility to NAFLD in a Bangladeshi population. However, due to the small sample size and limited number of TT individuals, further large‐scale and functional studies are required to validate these findings.

  • Open Access

    Gene‐Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium‐Glucose Cotransporter‐2 Inhibitors

    by Imran Hossain, Mahnoor Haidar, Mahfuj Ahmed Ratul, Jannatul Ferdous Sumona, Sraboni Shabnaz, Abul Fojal Nokib, Fatema‐ Tuz‐ Zohora

    Background: Inter‐individual variability in the therapeutic response to antidiabetic drugs is still a big problem in the management of type 2 diabetes mellitus (T2DM). Genetic polymorphisms of drug transporters, metabolizing enzymes and molecular targets have become significant factors in drug efficacy, pharmacokinetics and adverse effects. This review aims to provide a summary of the current evidence on the pharmacogenomics of metformin and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and their implications for precision medicine in T2DM. Methods: Published human studies examining genetic polymorphisms related to the various effects of metformin and SGLT2 inhibitors in patients with T2DM were systematically searched in PubMed, Scopus and EBSCO and analysed using an integrative review. Qualitative synthesis was used to compare the pharmacogenetic profiles of the two drug classes and to look for potential biomarkers for precision therapy. Results: Metformin has the most comprehensive pharmacogenetic evidence, including variants in SLC22A1 (OCT1), SLC22A2 (OCT2), SLC22A3 (OCT3), SLC47A1 (MATE1), SLC47A2 (MATE2), ATM and other genes that affect drug disposition, glycemic response and adverse effects. However, pharmacogenetic research on SGLT2 inhibitors is still scarce. Modest variations in drug exposure, glucose homeostasis and cardiorenal or hepatic outcomes have been reported for variants of UGT1A9, UGT2B4, SLC5A2, PNPLA3, and some glucose transporters, but most of these effects have not been strong enough to recommend routine genotype‐based therapy. Metformin has more robust and consistent pharmacogenetic associations overall, while SGLT2 inhibitors have emerging but less definitive associations. Conclusion: Pharmacogenomics has great promise to enhance the selection of antidiabetic drugs, maximize therapeutic effect and minimize side effects. There is current evidence for the clinical relevance of several pharmacogenetic markers for metformin, but evidence for SGLT2 inhibitors is preliminary. Further, large, prospective, multiethnic studies and genotype‐based clinical trials are needed to confirm candidate biomarkers and to help incorporate pharmacogenomics into precision medicine for T2DM.

  • Open Access

    Phytochemistry, biological activities, and toxicological insights into the genus Cyclea (Menispermaceae): A comprehensive review

    by Al-Ashiqur Rahman Alif, Hossain Imran, Tuz Zohora Fatema

    The genus Cyclea (Menispermaceae) comprises about 31 species distributed across southern and south-eastern Asia, several of which are long established in traditional and folk medicine, yet no genus-level synthesis of their chemistry, pharmacology, and safety exists. This review highlights the phytochemistry, biological activities, and toxicology of Cyclea spp., separates within-genus evidence from mechanistic data borrowed from related genera, and identifies research priorities. PubMed, Scopus, and Web of Science were accessed for recent literature on phytochemistry, pharmacology, and toxicity. The genus is chemically unified by bisbenzylisoquinoline alkaloids of tetrandrine, curine, and cycleanine types; tetrandrine is the marker alkaloid of C. peltata; C. barbata additionally yields azafluoranthene alkaloids, a phytoecdysone, and a gel-forming low-methoxyl pectin, and C. gracillima is rich in phenolic acids and flavonoids. Extracts and isolated constituents show anticancer, anti-inflammatory, antioxidant, antiplasmodial, antidiabetic, diuretic, hepatoprotective, and antivenom activities consistent with traditional use. Toxicological data are sparse and partly conflicting: an alkaloid extract of C. peltata gave an acute oral LD50 >2500 mg/kg in mice, whereas values for C. barbata leaf extracts span 617 to >30,000 mg/kg. Tetrandrine is a cytochrome P450-activated hepatic and pulmonary toxicant and a weak genotoxicant, and substitution by aristolochic acid-containing Aristolochia species remains unaddressed. With no clinical or pharmacokinetic study reported, safety margins cannot be calculated. Cyclea is a promising but underexplored source of bisbenzylisoquinoline alkaloids. Authenticated standardized material, bioassay-guided fractionation, rigorous in vitro and in vivo replication, and guideline-compliant toxicology and pharmacokinetics are prerequisites for clinical translation.

  • Open Access

    The Impact of Diabetes on Breast Cancer Development in Women: An Integrative Review

    by Israt Jahan, Mohammad Harun‐Ur‐Rashid, Imran Hossain, Fatema‐Tuz‐ Zohora

    Introduction: Increasing epidemiological evidence suggests that diabetes is associated with a modest but significant elevation in breast cancer risk, as well as poorer clinical outcomes following diagnosis. This integrative review critically synthesizes current epidemiological, biological and clinical evidence to elucidate the role of diabetes in breast cancer development and progression among women. Methods: We conducted a structured literature search (2010–2025) to identify original studies examining the relationship between diabetes and breast cancer risk and outcomes. English‐language human studies were included. Titles, abstracts and full texts were screened against predefined criteria, and relevant data were extracted and synthesized narratively. Results: Studies indicate that women with diabetes experience an increased incidence of breast cancer, with stronger associations observed in postmenopausal populations, and partial attenuation of risk following adjustment for obesity, highlighting both shared and independent metabolic contributions. Mechanistically, chronic hyperinsulinemia, altered insulin‐like growth factor signalling, low‐grade systemic inflammation, oxidative stress and oestrogen‐metabolic crosstalk are frequently proposed as biologically plausible pathways through which diabetes may influence breast carcinogenesis, particularly in hormone‐receptor‐positive tumours. Clinically, diabetes has been linked to delayed diagnosis, increased treatment‐related complications, and higher breast cancer‐specific mortality, underscoring the need for integrated metabolic and oncologic care. Conclusion: Diabetes mellitus, particularly type 2 diabetes, is consistently associated in observational studies with a small increment in breast cancer risk and a more clearly adverse impact on survival. Mechanistic and translational evidence supports biologically plausible pathways linking metabolic dysregulation to tumour initiation, progression and treatment tolerance, but definitive causal effects remain uncertain. Medication and biomarker‐based research and practice should be incorporated in metabolic‐oncologic care and research to enhance prevention and outcomes.


  • Open Access

    Association of GSTM1, GSTT1, and GSTP1 Gene Polymorphisms With Susceptibility to Periodontitis: A Systematic Review and Meta‐Analysis With Exploratory Analysis of Apical Periodontitis

    by Imran Hossain, Md. Saifuddin Molla, Fatema-Tuz- Zohora

    Background: Periodontitis is an inflammatory condition in which oxidative stress significantly contributes to tissue damage. Genetic polymorphisms in antioxidant enzymes, particularly glutathione S‐transferases (GSTs; GSTM1, GSTT1, and GSTP1), may influence an individual’s susceptibility to periodontal inflammatory conditions, including periodontitis and apical periodontitis (AP). However, prior studies have reported inconsistent results. Accordingly, this study evaluates the association between GST polymorphisms and periodontitis susceptibility, while also incorporating AP in an exploratory framework. Methods: Eight case–control studies were retrieved from PubMed, Scopus, and EBSCO. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a random‐effects model due to high heterogeneity. Subgroup analyses were conducted by genotype, disease type, and ethnicity, along with exploratory pooled analyses combining periodontitis and AP. Study quality was evaluated using the Newcastle–Ottawa Scale (NOS). Results: Exploratory pooled analyses indicated that the GSTM1 null genotype was associated with increased risk (OR = 2.84, 95% CI: 1.07–7.56, p = 0.04), whereas no significant association was identified in analyses restricted to periodontitis. In contrast, the GSTT1 null genotype and GSTP1 rs1695 polymorphism were not associated with periodontitis in either overall or subgroup analyses. The combined GSTM1/GSTT1 null genotype demonstrated a markedly elevated risk in the exploratory analysis (OR = 7.38, 95% CI: 1.69–32.19, p = 0.008), but this association was not evident in the periodontitis‐only subgroup. Significant associations were primarily driven by the AP subgroup, while results for periodontitis alone were inconsistent. Conclusions: GSTM1 and GSTT1 polymorphisms may contribute to susceptibility to oral inflammatory conditions, particularly AP, whereas the evidence for periodontitis remains inconclusive. The findings highlight the potential role of compromised antioxidant defenses in disease pathogenesis. These results must be interpreted with caution as there was considerable heterogeneity and a small number of studies. Larger studies are required to validate these findings and elucidate possible mechanisms.

  • Open Access

    Association of the rs688 Polymorphism in the Gene Encoding Low‐Density Lipoprotein Receptor in Bangladeshi Population With Coronary Artery Disease

    by Imran Hossain, Nahid Sharmin, Istiaque Ahmed, Golam Saklayen, Sauda Sumaya Dina, Sheikh Zahir Raihan

    Background: Coronary artery disease (CAD) is among the leading causes behind the morbidity and mortality of the world population. Among others, low‐density lipoprotein (LDL) is one of the main drivers behind the development of CAD, and the LDL receptor (LDLR) plays a central role in cholesterol homeostasis by facilitating the clearance of LDL cholesterol from the blood. The LDLR rs688 single‐nucleotide polymorphism in exon 12 has been reported to influence mRNA splicing efficiency, potentially modifying receptor function and lipid metabolism. The aim of this study was to assess the association between LDLR rs688 polymorphism and CAD susceptibility among CAD patients in the Bangladeshi population and to determine its relationship with serum LDL level. Methods: A case–control study was conducted involving 225 participants, including 150 CAD patients and 75 healthy controls. High‐density lipoprotein, LDL, triglycerides, and total cholesterol were measured by biochemical tests using appropriate kits. The LDLR genotype was identified using the allele‐specific PCR (AS‐PCR) technique. Results: Relative to the control group, the CAD group showed a higher distribution frequency of the TT genotype (17.33%) and a lower frequency of the CC genotype (15.33%). The LDLR rs688 TT genotype showed significant association with CAD among Bangladeshi patients (OR = 3.617, 95% CI: 1.089–10.05; p = 0.0352). Furthermore, individuals carrying the TT and CT genotypes exhibited higher LDL levels compared with those carrying the CC genotype ( p < 0.05). Finally, univariate and multivariate logistic regression analyses revealed that the LDLR rs688 TT genotype remained significantly associated with CAD after adjustments for covariates ( p < 0.05). Conclusion: This hospital‐based case–control study provides preliminary evidence of an association between the LDLR rs688 TT genotype and CAD in a Bangladeshi population. These findings are preliminary and require validation in larger, population‐based studies.